肿瘤药学2016，Vol.6Issue(1)：70-73,4.DOI:10.3969/j.issn.2095-1264.2016.01.16
XELOX方案与FOLFOX方案新辅助化疗对进展期直肠癌患者的疗效比较
Comparison of the Clinical Effects between XELOX and FOLFOX as Neoadjuvant Chemotherapy on Advanced Retal Carcinoma
何盛泉 1赖家骏 1张涛 1翁伟明 1胡志伟1
作者信息
- 1. 粤北人民医院胃肠外科，广东 韶关，512026
- 折叠
摘要
Abstract
Objective To compare the clinical effects, toxicities and survival rate between XELOX and FOLFOX regi-mens as neoadjuvant chemotherapy for patients with advanced retal carcinoma. Methods A total of 71 patients with ad-vanced retal carcinoma in our hospital were selected and randomly divided into observation group (35 cases) and control group (36 cases). The observation group was treated with XELOX regimen before operation while the control group with FOLFOX regimen. All the patients received laparoscopic total mesorectal excision after neoadjuvant chemotherapy. Patients went on the same way of chemotherapy in each group after operation. The clinical effects, toxicity, surgical data, survival rate of the two groups were collected and analyzed. Results There was no statistic difference in clinical effects, surgical time, in-traoperative blood loss, time for removing drainage tube, time for anal exhaust, hospitalization time, tumor-free survival rate and overall survival rate between the two groups. The rate of leukocyte decrease was significantly lower in observation group (31.42﹪) than in control group (55.55﹪), while the rate of hand-foot syndrome was significantly higher in observation group (48.57﹪) than in the control group (0﹪). Conclusion XELOX regimen is as effective as FOLFOX regimen. It is an accept-able alternative option of neoadjuvant chemotherapy.关键词
直肠癌/新辅助化疗/XELOXKey words
Rectal carcinoma/Neoadjuvant chemotherapy/XELOX分类
医药卫生引用本文复制引用
何盛泉,赖家骏,张涛,翁伟明,胡志伟..XELOX方案与FOLFOX方案新辅助化疗对进展期直肠癌患者的疗效比较[J].肿瘤药学,2016,6(1):70-73,4.
